Tuesday , October 24 2017
Home / Resources / Products / FDA Approves Azilsartan, another ARB, for Hypertension

FDA Approves Azilsartan, another ARB, for Hypertension

 

TakedaThe FDA approved a new angiotensin-receptor blocker (ARB), azilsartan medoxomil (Takeda Pharmaceutical), for the treatment of hypertension in adults. The drug will be available in 80-mg and 40-mg doses, although 80 mg is the recommended dose. The 40-mg dose is available for clinicians who wish to combine the drug in patients treated with high-dose diuretic therapy. In phase 3 studies, azilsartan at its highest dose was more effective in lowering 24-hour blood pressure than two of its ARB rivals, olmesartan (Benicar, Daiichi Sankyo) and valsartan (Diovan, Novartis).